NYSE:RMD - ResMed Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$107.03 +0.22 (+0.21 %)
(As of 06/21/2018 04:00 PM ET)
Previous Close$106.81
Today's Range$106.22 - $107.59
52-Week Range$71.29 - $107.67
Volume420,475 shs
Average Volume684,492 shs
Market Capitalization$15.14 billion
P/E Ratio37.95
Dividend Yield1.32%
Beta0.93
ResMed logoResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; and data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:RMD
CUSIP76115210
Phone858-836-5000

Debt

Debt-to-Equity Ratio0.39
Current Ratio3.48
Quick Ratio2.85

Price-To-Earnings

Trailing P/E Ratio37.95
Forward P/E Ratio30.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.07 billion
Price / Sales7.39
Cash Flow$3.6517 per share
Price / Cash29.31
Book Value$13.82 per share
Price / Book7.74

Profitability

EPS (Most Recent Fiscal Year)$2.82
Net Income$342.28 million
Net Margins13.52%
Return on Equity23.72%
Return on Assets13.66%

Miscellaneous

Employees6,080
Outstanding Shares142,740,000

ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, April 26th. Shareholders of record on Thursday, May 10th will be given a dividend of $0.35 per share on Thursday, June 14th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.31%. The ex-dividend date is Wednesday, May 9th. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) issued its earnings results on Thursday, April, 26th. The medical equipment provider reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.07. The medical equipment provider earned $591.60 million during the quarter, compared to the consensus estimate of $575.75 million. ResMed had a return on equity of 23.72% and a net margin of 13.52%. The firm's revenue for the quarter was up 15.1% on a year-over-year basis. During the same period last year, the firm earned $0.71 EPS. View ResMed's Earnings History.

When is ResMed's next earnings date?

ResMed is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for ResMed.

What price target have analysts set for RMD?

12 brokerages have issued 12-month price targets for ResMed's shares. Their predictions range from $55.00 to $90.00. On average, they anticipate ResMed's share price to reach $68.80 in the next year. View Analyst Ratings for ResMed.

What are Wall Street analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:
  • 1. According to Zacks Investment Research, "Over the past three months, ResMed has outperformed its industry. The company achieved solid double-digit global revenue growth in the last reported quarter, led by sales from Software-as-a-Service businesses as well as new mask products and devices. The company is also focusing on product innovation through research and development. In terms of recent developments, the company recently received reimbursement approval for mandibular repositioning devices in France. Further, the company announced that South Korea will start reimbursing diagnosis and therapeutic treatment for sleep apnea in the near term. All these factors boost investor faith in the stock. Yet, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to challenging pricing scenario. Rising costs and a weak gross margin are other concerns." (6/12/2018)
  • 2. Needham & Company LLC analysts commented, "We worked with Sleep Review magazine to survey US sleep centers. The survey included 136 responses received between 1/30/18 and 2/19/18. Compared to our prior (3Q17) survey, actual last-12-month patient volume growth decreased slightly while expected next-12-month patient volume growth increased slightly. RMD’s flow generator ratings were in line with Respironics’ ratings while RMD’s mask ratings were the highest but only slightly above its competitors’ ratings. RMD looks likely to gain branded flow generator prescription share but to lose branded mask prescription share. Overall, we think that the survey is mixed for RMD and we maintain our Hold rating." (3/7/2018)

Who are some of ResMed's key competitors?

Who are ResMed's key executives?

ResMed's management team includes the folowing people:
  • Mr. Michael J. Farrell BE, SM, MBA, Chief Exec. Officer and Director (Age 46)
  • Mr. Robert A. Douglas, Pres & COO (Age 58)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 51)
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 59)
  • Mr. James Hollingshead, Pres of Sleep Bus. (Age 55)

Has ResMed been receiving favorable news coverage?

Media coverage about RMD stock has trended somewhat positive recently, Accern reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ResMed earned a news impact score of 0.08 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 45.19 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.84%), Baillie Gifford & Co. (3.41%), Northern Trust Corp (1.15%), JPMorgan Chase & Co. (0.68%), Millennium Management LLC (0.54%) and Legal & General Group Plc (0.52%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Mchale, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Bahl & Gaynor Inc., Guggenheim Capital LLC, Swiss National Bank, Baillie Gifford & Co., Northern Trust Corp, Copeland Capital Management LLC, Prudential Financial Inc. and Russell Investments Group Ltd.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell, Richard Mchale, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

Which major investors are buying ResMed stock?

RMD stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Rockefeller Capital Management L.P., Great Lakes Advisors LLC, Bellevue Group AG, State of Tennessee Treasury Department, BlackRock Inc. and Eaton Vance Management. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $107.03.

How big of a company is ResMed?

ResMed has a market capitalization of $15.14 billion and generates $2.07 billion in revenue each year. The medical equipment provider earns $342.28 million in net income (profit) each year or $2.82 on an earnings per share basis. ResMed employs 6,080 workers across the globe.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]


MarketBeat Community Rating for ResMed (RMD)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  470 (Vote Underperform)
Total Votes:  689
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.